Nature News

Exploit innate immunity within the remedy of most cancers

1.

Okazaki, T. and Honjo, T. Ligands PD-1 and PD-1: from discovery to scientific software. Int. Immunol. 19, 813-824 (2007).

2

Pagès, F. et al. Worldwide Validation of the Immunoscore Consensus for Classification of Colon Most cancers: Prognostic and Precision Research. Lancet 391, 2128-2139 (2018).

Three

June, C.H., O. Connor, R.S., Kawalekar, O.U., Ghassemi, S. & Milone, M.CAR. T cell primarily based immunotherapy for human most cancers. Science 359, 1361-1365 (2018).

Four

Chen, D. S. & Mellman, I. Oncology Meets Immunology: The Most cancers Cycle and Immunity. Immunity 39, 1-10 (2013). Definition of the most cancers – immunity cycle.

5

Chen, D. S. & Mellman, I. Parts of Immunity Towards Most cancers and Most cancers Set Level and Immunity. Nature 541, 321-330 (2017).

6

Mellman, I., Coukos, G. and Dranoff, G. Immunotherapy of most cancers reaches its maturity. Nature 480, 480 to 489 (2011).

seven.

Medzhitov, R. & Janeway, C.A. Jr. Inborn immune induction of the adaptive immune response. Chilly Harb Spring. Symp. As. Biol. 64, 429-435 (1999).

Eight

Vivier, E. et al. Innate lymphoid cells: 10 years later. Cell 174, 1054-1066 (2018).

9

Pradeu, T., S. Jaeger and E. Vivier. The velocity of change: in direction of a principle of discontinuous immunity? Nat. Rev. Immunol. 13, 764-769 (2013).

ten.

Broz, M.L. et al. The dissection of the myeloid compartment of the tumor reveals uncommon cells with activating antigen which can be important for the immunity of T cells. Most cancers Cell 26, 638-652 (2014).

11

Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89-94 (2019).

12

Hildner, Okay. et al. Batf3 deficiency reveals a vital function for CD8α + dendritic cells within the immunity of cytotoxic T cells. Science 322, 1097-1100 (2008). An indication of the function of cDC1 in most cancers.

13

Poulin, L. F. et al. Characterization of human DNG-1 + BDCA3 + leukocytes as suspected equivalents of mouse CD8α + dendritic cells. J. Exp. Med. 207, 1261-1271 (2010).

14

Sancho, D. et al. Tumor remedy in mice by way of an antigen concentrating on a novel CD-restricted kind C lectin. J. Clin. Make investments. 118, 2098-2110 (2008).

15

Fuertes, M.B. et al. IFN kind I alerts are required for CD8 + antitumor T cell responses by way of CD8α + dendritic cells. J. Exp. Med. 208, 2005-2016 (2011).

16

Spranger, S., D. Dai, B. Horton and Gajewski, T. F. Batf3 tumor-resident dendritic cells are required for effector T-cell trafficking and adoptive T-cell remedy. Most cancers Cell 31, 711-723 (2017).

17

Barry, Okay.C. et al. An axis of natural-dendritic killer cells defines tumor microenvironments delicate to regulate level remedy. Nat. Med. 24, 1178-1191 (2018).

18

Schumacher, T.N. & Schreiber, R.D. Neo-antigens in most cancers immunotherapy. Science 348, 69-74 (2015).

19

Raulet, D.H. & Guerra, N. Oncogenic Stress Detected by the Immune System: The Position of Pure Killer Cell Receptors. Nat. Rev. Immunol. 9, 568-580 (2009).

20

Vivier, E. et al. Innate or adaptive immunity? The instance of pure killer cells. Science 331, 44-49 (2011).

21

Bottcher, J.P. et al. NK cells stimulate the recruitment of cDC1 within the tumor microenvironment, thus selling the immune management of most cancers. Cell 172, 1022-1037 (2018).

22

Buck, M.D., Sowell, R.T., Kaech, S.M. & Pearce, E.L. Metabolic Instruction of Immunity. Cell 169, 570-586 (2017).

23

Marabelle, A., Tselikas, L., Baere, T. and Houot, R. Intratumoral Immunotherapy: Utilizing the tumor as a treatment. Ann. Oncol. 28 (suppl 12), xii33 to xii43 (2017).

24

Houot, R. & Levy, R. T-cell modulation mixed with intratumoral CpG cures lymphoma in a mouse mannequin with out the necessity for chemotherapy. Blood 113, 3546-3552 (2009).

25

Marabelle, A. et al. Exhaustion of tumor-specific Tregs at a single web site eliminates disseminated tumors. J. Clin. Make investments. 123, 2447 to 2463 (2013).

26

Sagiv-Barfi, I. et al. Eradication of spontaneous malignant tumors by native immunotherapy. Sci. Trad. Med. 10, eaan4488 (2018).

27

Ribas, A. et al. SD-101 together with pembrolizumab in superior melanoma: outcomes of a multicenter section Ib examine. Discov most cancers. Eight, 1250-1257 (2018). Medical trial displaying the efficacy of intratumoral injections of TLR9 agonists in most cancers sufferers.

28

Milhem, M. et al. Part 1b / 2, multicenter, open-label examine of the mixture of SD-101 and pembrolizumab in sufferers with superior melanoma and naive anti-PD-1 remedy. J. Clin. Oncol. 37, 9534 (2019).

29

Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic anti-tumor immunity. Proc. Natl Acad. Sci. USA 112, 15408-15413 (2015).

30

Corrales, L. et al. The direct activation of STING within the tumor microenvironment results in potent and systemic tumor regression and immunity. Cell Rep. 11, 1018-1030 (2015).

31.

Sivick, Okay.E. et al. The magnitude of therapeutic activation of STING determines anti-tumor immunity mediated by CD8 + T cells. Cell Rep. 25, 3074-3085 (2018).

32

Harrington, Okay. et al. Preliminary outcomes of the unpublished examine (FIH) of MK-1454 interferon stimulating gene agonist (STING), alone or together with pembrolizumab (pembro) in sufferers with strong tumors or strong lymphomas. Ann. Oncol. 29, mdy424.Zero15 (2018).

33

Middleton, M. et al. Part I / II, open-label multicenter examine on the intratumoral / intralesional administration of the retinoic acid-induced gene (MK-4621) activator (RIG-I) in sufferers with superior tumors or recurring. Ann. Oncol. 29, mdy424.Zero16 (2018).

34

McPherson, A. et al. Divergent patterns of clonal unfold and intraperitoneal mixing in serous ovarian most cancers of excessive grade. Nat. Broom. 48, 758-767 (2016).

35

Jimenez-Sanchez, A. et al. Heterogeneous tumor immunized microenvironments amongst differential progress metastases in a affected person with ovarian most cancers. Cell 170, 927-938 (2017).

36

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. and Kroemer, G. Immunogenic cell dying in most cancers and infectious illnesses. Nat. Rev. Immunol. 17, 97-111 (2017).

37

Rios-Doria, J. et al. Doxil synergizes with most cancers immunotherapies to enhance antitumor responses in syngeneic mouse fashions. Neoplasia 17, 661-670 (2015).

38

Abruzzo, M. P. et al. The inhibition of bromodomain and extra-terminal proteins (BET) will increase MICA expression of NKG2D ligand and its sensitivity to NK cell-mediated cytotoxicity in a number of myeloma cells: the function of the NKG2D ligand. cMYC-IRF4-miR-125b interplay. J. Hematol. Oncol. 9, 134 (2016).

39

Cao, G. et al. Tumor therapies act as stress inducers to extend tumor sensitivity to cytolysis of NK (Pure Killer) cells by positively regulating NKp30 B7-H6 ligand. J. Biol. Chem. 290, 29964-29973 (2015).

40

Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to the management of the tumor by a mix of cytostatic medicine. Science 362, 1416-1422 (2018).

41

Garg, A.D. et al. Medical trial: induction of immunogenic cell dying by most cancers chemotherapy. OncoImmunology 6, e1386829 (2017).

42

Schmid, P. et al. Atezolizumab and nab-paclitaxel in superior triple unfavorable breast most cancers. N. Engl. J. Med. 379, 2108-2121 (2018).

43

Apetoh, L. et al. Toll-like receptor Four-contribution of the immune system to most cancers chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).

44

Obeid, M. et al. Publicity to calreticulin is critical for the immunogenicity of gamma irradiation and apoptosis induced by UVC mild. Distinction of cell dying. 14, 1848-1850 (2007).

45

Deng, L. et al. Detection of STING-dependent cytosolic DNA promotes radiation-induced kind I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843-852 (2014).

46

Fiorica, F. et al. Nivolumab, immune management level inhibitor, and radiotherapy in pretreated sufferers with lung most cancers: effectiveness and security of the affiliation. A m. J. Clin. Oncol. 41, 1101-1105 (2018).

47

Luke, J.J. et al. Security and scientific exercise of pembrolizumab and stereotactic radiotherapy of the multisite physique in sufferers with superior strong tumors. J. Clin. Oncol. 36, 1611-1618 (2018).

48.

Vanpouille-Field, C. et al. The Trex1 exonuclease DNA regulates tumor immunogenicity induced by radiotherapy. Nat. Frequent. Eight, 15618 (2017).

49

Salmon, H. et al. Enlargement and activation of CD103 + dendritic cell progenitors on the tumor web site improve tumor response to the therapeutic inhibition of PD-L1 and BRAF. Immunity 44, 924-938 (2016).

50

Hammerich, L. et al. Systemic scientific regressions of tumors and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814-824 (2019).

51.

Dranoff, G. et al. Vaccination with irradiated tumor cells designed to secrete murine issue stimulating granulocyte-macrophage colonies stimulates potent, particular and long-lasting antitumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).

52.

Mach, N. et al. Variations in dendritic cells stimulated in vivo by tumors designed to secrete granulocyte-macrophage colony stimulating issue or Flt3 ligand. Most cancers Res. 60, 3239-3246 (2000).

53

Nasi, M.L. et al. The intradermal injection of granulocyte and macrophage colony stimulating issue (GM-CSF) in sufferers with metastatic melanoma recruits dendritic cells. Cytokines Cell. Mol. Ther. 5, 139-144 (1999).

54

Andbacka, R.H. et al. Talimogene laherparepvec improves the sustainable response fee in sufferers with superior melanoma. J. Clin. Oncol. 33, 2780-2788 (2015).

55

Chesney, J. et al. Randomized, open-label, section II examine evaluating the efficacy and security of natural medication with talimogen together with ipilimumab versus ipilimumab alone in sufferers with superior melanoma , unresectable. J. Clin. Oncol. 36, 1658-1667 (2018).

56.

Ribas, A. et al. Oncolytic virotherapy promotes intratumoral infiltration of T cells and enhances anti-PD-1 immunotherapy. Cell 174, 1031-1032 (2018).

57

L. Zitvogel, L. L., Kepp, O., Smyth, M.J. & Kroemer, G. Kind I interferons in anti-cancer immunity. Nat. Rev. Immunol. 15, 405-414 (2015).

58.

Diamond, M.S. et al. Kind I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989-2003 (2011).

59

Dunn, G.P. et al. A vital perform for kind I interferons within the immuno-modification of most cancers. Nat. Immunol. 6, 722-729 (2005). Research describing the function of kind I IFNs in most cancers.

60.

Le Mercier, I. et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by remedy of TLR7 ligand. Most cancers Res. 73, 4629-4640 (2013).

61.

Wang, S. et al. The intratumoral injection of a CpG oligonucleotide restores blocking resistance to PD-1 by growing multifunctional CD8 + T cells. Proc. Natl Acad. Sci. USA 113, E7240 to E7249 (2016).

62

Wennerberg, E., Kremer, V., Childs, R. and Lundqvist, A. CXCL10-induced migration of adoptively transferred human killer cells to strong tumors causes regression of tumor progress in vivo. Most cancers Immunol. Immunother. 64, 225-235 (2015).

63.

Swann, J. B. et al. IFN kind I contributes to the homeostasis, activation and antitumor perform of NK cells. J. Immunol. 178, 7540-7549 (2007).

64.

Huang, T.H., Chintalacharuvu, Okay.R. & Morrison, S.L. Focusing on lymphoma of IFN-α cells to B by a tumor-specific antibody triggers potent anti-tumor actions. J. Immunol. 179, 6881-6888 (2007).

65.

Rossi, E.A. et al. Preclinical research on the focused supply of a number of IFNα2b to HLA-DR in numerous hematologic cancers. Blood 118, 1877-1884 (2011).

66.

Yang, X. et al. Focusing on the microenvironment of the tumor with interferon-β hyperlinks innate and adaptive immune responses. Most cancers cell 25, 37-48 (2014).

67.

Cauwels, A. et al. The discharge of kind I interferon to dendritic cells enhances the effectiveness of tumor eradication and immune affiliation therapies. Most cancers Res. 78, 463-474 (2018).

68.

Monticelli, L. A. et al. Innate lymphoid cells promote homeostasis of lung tissue after an infection with the influenza virus. Nat. Immunol. 12, 1045-1054 (2011).

69

Van Gool, F. et al. Group 2 lymphoid innate cells producing interleukin-5 management the eosinophilia induced by remedy with interleukin-2. Blood 124, 3572-3576 (2014).

70.

Berntsen, A., Brimnes, Straten MK, P. and Svane, IM Elevated variety of circulating CD4 + CD25highp3 + regulatory T lymphocytes in sufferers with metastatic renal cell carcinoma throughout remedy with dendritic cell vaccination and low-dose interleukin-2. J. Immunother. 33, 425-434 (2010).

71.

Sim, G.C. et al. IL-2 remedy promotes ICOS + Treg suppressive enlargement in sufferers with melanoma. J. Clin. Make investments. 124, 99-110 (2014).

72.

Hurwitz, M. et al. Primary tumor immune signatures related to the response to leukine bazegal (NKTR-214) and nivolumab. J. Clin. Oncol. 37, 2623 (2019).

73.

Tannir, N. et al. A randomized, open-label, section III examine evaluating leukine routine (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator selection) in sufferers with superior untreated renal cell carcinoma. J. Clin. Oncol. 37, TPS4595 (2019).

74.

Khushalani, N. et al. CA045-001: Randomized open-label, open-label, Part III examine of monotherapy with Bempegaldesleukine monotherapy (NKTR-214) and nivolumab (NIVO) versus NIVO in sufferers with beforehand untreated melanoma , unresectable or metastatic (MEL). J. Clin. Oncol. 37, TPS9601 (2019).

75.

Huntington, N. D. et al. The transcribed presentation of IL-15 promotes the event and differentiation of human NK cells in vivo. J. Exp. Med. 206, 25-34 (2009).

76.

Uchida, J. et al. The innate community of mononuclear phagocytes depletes B lymphocytes by way of Fc receptor-dependent mechanisms throughout anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).

77.

Gerdes, C.A. et al. GA201 (RG7160): a brand new humanized anti-EGFR antibody, glyco-modified with enhanced ADCC and in vivo efficacy superior to that of cetuximab. Clin. Most cancers Res. 19, 1126-1138 (2013).

78.

Paz-Ares, L.G. et al. Part I pharmacokinetic and pharmacodynamic dose-escalation examine of RG7160 (GA201), the primary glyco-engineering monoclonal antibody to the epidermal progress issue receptor, in sufferers with superior strong tumors. J. Clin. Oncol. 29, 3783-3790 (2011).

79.

Herter, S. et al. Preclinical exercise of kind II anti-CD20 antibody, GA101 (obinutuzumab), in comparison with that of rituximab and ofatumumab in vitro and in xenograft fashions. Mol. Most cancers Ther. 12, 2031-2042 (2013).

80.

Stockert, E. et al. Investigation of the humoral immune response of most cancers sufferers to a panel of human tumor antigens. J. Exp. Med. 187, 1349-1354 (1998).

81.

Reuschenbach, M., von Knebel Doeberitz, M. and Wentzensen, N. Systematic evaluate of humoral immune responses towards tumor antigens. Most cancers Immunol. Immunother. 58, 1535-1544 (2009).

82.

Murphy, M.A., O'Leary, J.J. and Cahill, D.J. Analysis of humoral immune response to most cancers. J. Proteomics 75, 4573-4579 (2012).

83.

Daëron, M., Malbec, O., Latour, S., Arock, M. and Fridman, WH Regulation of mast cell activation mediated by the excessive affinity IgE receptor by receptors of Murine low affinity IgG. J. Clin. Make investments. 95, 577-585 (1995).

84.

Schreiber, H., Wu, T.H., Nachman, J. & Rowley, D. A. Immunological enchancment of major tumor improvement and its prevention. Semin. Most cancers Biol. 10, 351-357 (2000).

85.

Clynes, R.A., Towers, T.L., Presta, L.G. and Ravetch, J.V. Inhibitory Fc receptors modulate cytotoxicity in vivo towards tumor targets. Nat. Med. 6, 443-446 (2000). Descr